In the development of advanced therapeutics such as CAR-T cells, dendritic cell (DC) vaccines, and radiopharmaceuticals, the questions that decide a program are spatial and temporal. Where do the cells go, do they reach the target, and how long do they stay. Conventional techniques, histopathology and ex vivo fluorescence analysis among them, answer those questions poorly, because they are terminal by design and cannot produce continuous, whole-body dynamic data.
To address these limitations, non-human primate (NHP) models combined with clinical-grade PET/CT imaging have emerged as a highly translatable platform for longitudinal, quantitative, and non-invasive tracking of immune cells and molecular probes. The approach allows real-time visualization of biological processes under physiological conditions that resemble the human system closely.
At Prisys Biotech, this capability is integrated into a translational imaging platform that supports both cell therapy evaluation and novel PET tracer development within a clinically relevant framework.
Longitudinal In Vivo Tracking of Immune Cells
A central challenge in cell therapy development is the ability to accurately characterize the in vivo kinetics of infused cells, including their biodistribution, migration, expansion, and tissue-specific homing. Plasma sampling can show that a product persists, but not where it went, and a tissue biopsy taken at necropsy gives one snapshot of one site.
Prisys Biotech employs radiolabel-based cell tracking strategies combined with high-resolution PET/CT imaging to address this need. Immune cells such as T cells or dendritic cells can be labeled ex vivo using positron-emitting isotopes, enabling sensitive and quantitative detection after re-infusion into NHP models.
One of the most widely used isotopes in this context is Zirconium-89 (⁸⁹Zr). With a physical half-life of approximately 3.27 days, ⁸⁹Zr is particularly well-suited for mid- to long-term tracking studies, allowing repeated imaging over several days without significant signal loss. Following administration, whole-body PET/CT scans can be performed at predefined time points to generate quantitative biodistribution maps.

This approach provides several key advantages:
- Enables non-terminal, longitudinal assessment of cell fate
- Supports quantitative analysis of tissue-specific accumulation (e.g., lymph nodes, spleen, bone marrow, tumor or inflammatory sites)
- Facilitates evaluation of targeting efficiency, systemic safety, and retention time
- Reduces inter-animal variability by allowing repeated measurements in the same subject
The last point matters more than it first appears. Cell products vary between batches, and animal-to-animal differences in immune background are substantial. When each animal is imaged before and after dosing, the comparison stays internal and the variance that comes from cohort composition drops out.
Because the work is done in NHP models, the data reflect immune system behavior close to the clinical case, which improves the predictive value for human studies.
Development and Validation of Novel PET Tracers
Beyond tracking therapeutic cells, the same imaging platform supports the development of novel PET tracers for diagnostic and theranostic applications.
In early-stage tracer development, it is essential to evaluate:
- Target specificity and binding affinity
- In vivo stability and metabolic profile
- Whole-body distribution and clearance pathways
- Radiation dosimetry and safety
Rodent models often fail to fully capture the complexity of human physiology, particularly for tracers targeting immune, neurological, or metabolic pathways. A tracer that clears through a pathway absent or differently expressed in the mouse will look acceptable there and behave differently in the clinic. NHP models provide high anatomical and physiological similarity to humans, which is why they sit as a bridge between small animal studies and clinical trials.
Prisys Biotech enables end-to-end tracer evaluation, including:
- Radiolabeling strategy development and optimization
- PET/CT imaging protocol design aligned with clinical standards
- Quantitative image analysis and kinetic modeling
- Correlation with bio-sampling data (Pharmacokinetics (PK), Pharmacodynamics (PD), biomarker analysis)
Integrated Translational Imaging Platform at Prisys Biotech
What carries this work is not the scanner alone. It is the integration of several translational capabilities inside one platform: radiochemistry, imaging, and bioanalysis reporting into a single study file, which is what keeps a program from stalling between the imaging suite and the analytical lab.
Prisys Biotech operates a clinical-equivalent imaging infrastructure, including PET/CT, MRI, CT, and DSA systems, supported by experienced radiologists and multidisciplinary scientific teams. These capabilities enable:
- Cross-modality imaging for thorough evaluation of disease and therapeutic response
- Image-guided interventions, including targeted delivery and biopsy
- Quantitative endpoint definition aligned with clinical trial methodologies
In addition, the platform is embedded within a broader NHP translational research ecosystem, which includes:
- A diverse portfolio of disease models across CNS/Neurology, Immunology & Inflammation, respirology, and cardiometabolism indications
- PK/PD and bioanalytical capabilities for integrated pharmacological assessment
- Advanced technologies such as MRI-Guided Drug Delivery For CNS Research and AI-based NHP Behavior Analysis System
- Animal-Welfare (AAALAC-accredited) facilities ensuring high standards of animal welfare and regulatory compliance
Conclusion
In vivo immune cell tracking and PET tracer development represent critical components of modern drug development, particularly in the fields of immunotherapy, oncology, and precision medicine.
By combining non-human primate models with Clinical Imaging technologies, researchers can achieve:
- Direct visualization of cellular and molecular dynamics in living systems
- Quantitative, longitudinal data supporting decision-making
- Enhanced translational relevance for clinical development
Prisys Biotech provides an integrated platform that bridges the gap between preclinical research and clinical application, enabling better-informed evaluation of therapeutic strategies and shortening the path from candidate selection to the diagnostics and treatments that reach patients.
FAQ
Q: Why are NHP models important for immune cell tracking studies?
A:
Q: What advantages does ⁸⁹Zr labeling provide in PET imaging?
A:
Q: How does Prisys support PET tracer development?
A:













